They indicated a 22% increase in the original PKS business in the first quarter, but this is off a very small base.
Very little information on the bulk of the former Potential(x) activities which formed half of the Beamtree revenue stream after the acquisition. The announcement finally mentions "Health Roundtable" as the main part of the analytics business with a 10% increase in revenue (on a "like for like basis" whatever that really means). However they didn't mention their other analytic clients, such as the Ability Roundtable, Hospital Benchmarking Network, or Australian Private Hospital Association network that were prominent in the Potential X purchase announcement.
They also don't mention the departure of the key Potential x executive or what his intentions are regarding his 11 million shares that are now potentially weighing on the sell side on the market now that they are no longer in voluntary escrow. It would have been much more helpful to see more information on sales and costs for each line of business.
Why am I getting the feeling that stockholders are being treated as mushrooms??
BMT Price at posting:
23.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)